The last decade has proved noticeable in the battle against TB as it is after many years that the TB drug discovery pipeline is being flooded with molecules that have gone up to different stages of the clinical trials. 1 Most importantly there has been a marginal decline in the incidence rate. 2 In spite of this, winning the battle against this disease remains a herculean task, as the battle took a different dimension in the form of multidrug-resistant (MDR) and extensively ...